Genetic Testing in Lung Cancer
Identification of actionable mutations, deletions and driver gene fusions in NSCLC and SCLC can help guide targeted treatment regimens
Testing Solutions
9+1 
Target Genes

1. EGFR
2. BRAF
3. MET
4. ERBB2
5. KRAS
6. ALK
7. RET
8. ROS
9. NTRK + PDL-1

Highlights of Genetic Testing Panel

  • Liquid Biopsy - Cell free DNA for EGFR available
  • TAT for complete Oncomine Panel 2 weeks only
  • Tests available individually also
  • Fresh tissue / FFPE block accepted
Includes Mutations, Deletions, Fusion genes and PDL-1 overexpression commonly reported in NSCLC and SCLC
EFGR - by Liquid Biopsy

Individual Testing Solutions for Lung Cancer

EGFR Mutation Testing*
To detect mutations in the EGFR gene for the detection of 42 mutations 
(exons 18, 19, 20, and 21)
Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 5 days
Liquid Biopsy Available
KRAS Mutation Testing
To detect mutations in the KRAS oncogene for detection of 7 mutations in codon 12 and 13
Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 5 days
BRAF Mutation Testing
To detect hotspot mutation in V600E codon of exon 15 in the BRAF gene
Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 7 days
ROS-1 by FISH
To detect the ROS1 gene rearrangement
Sample type – FFPE tissue block
Method – Fluorescence In Situ Hybridization
TAT – 7 days
ALK by IHC
To detect for ALK gene rearrangement
Sample type – FFPE tissue block
Method – Immunohistochemistry (IHC)
TAT – 4 days
PDL - 1 Testing
To detect over expression of PDL-1 by tumor and Immune cells SP-142 Clone Ventana
Sample type – FFPE tissue block
Method – Immunohistochemistry (IHC)
TAT – 4 days
Central Processing Center
Anderson Diagnostics and Labs,
No.26, Rajarathinam Street,
Kilpauk, Chennai - 600010.
HELP LINE
+917305988862

Oncomine Focus Assay Panel for Lung Cancer with PDL-1 Testing

  • Hot spot screening of relevant, druggable mutations, copy number changes and fusions for various Cancers

  • ACMG/AMP guidelines-based reporting with drugs and target information

  • NGS based assay eliminates need of multiple technology FISH, IHC, Realtime

  • Complete screening of relevant gene in single sample

Sample Type
FFPE Block or Fresh Tissue in ONCO-Bank
TAT - 2 to 3 weeks
Gene Molecular aberration Prevalence in NSCLC Prevalence in SCC
EGFR Mutations (exons 18 – 21) 28% 9%
BRAF Mutations 5% 4%
MET Mutations 10% 4%
RET Fusions or rearrangements 4% 4%
ERBB2 To detect mutations 7% 5%
KRAS To detect mutations 23% 5%
ALK Fusions or rearrangements 7% 5%
ROS Fusions or rearrangements 4% 8%
NTRK Fusions or rearrangements 3% 6%

(Adapted from cbioportal.org)

List of FDA Approved Targeted Drugs Covered

Biomarker Drugs Disease
BRAF V600E; BRAF V600K Vemurafenib, Cobimetinib, Dabrafenib, Trametinib, Atezolizumab, Encorafenib Melanoma, NSCLC, CRC
ALK Fusion, EML4-ALK Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib NSCLC
EGFR Cetuximab, Mobocertinib, Afatinib, Gefitinib, Amivantamb, Osimertinib, Erlotinib Lung cancer
ERBB2 Fam-trastuzumab Deruxtecan-nxki NSCLC
KRAS Cetuximab, Panitumumab, Sotorasib CRC, NSCLC
MET, exon skipping Capmatinib NSCLC
RET-Fusions Pralsetinib, Selpercatinib NSCLC
Ros1-fusions Entrectinib, Crizotinib NSCLC
Greams Road
PURASAIWALKKAM CENTRE
Central Pathology Lab
Central Genetic Lab
© 2023 Anderson Diagnostics & Labs. All rights are reserved.
HTML SitemapPrivacy PolicyCareers
Designed by
Digital SEO
magnifiercrosstext-align-justify